krazati
Promising Outcomes and Safety Profile of Krazati Combined with Pembrolizumab in Treatment-Naïve, Advanced NSCLC Patients with KRASG12C Mutation: Insights from the Phase II/III KRYSTAL-7 Study (ESMO 2023)
ESMO 2023: LBA65 NSCLC with KRAS mutations is a difficult market with few treatment options and many unmet needs. Krazati ...
Bristol Myers Squibb acquires Mirati Therapeutics in a $5.8 billion deal to expand its cancer treatment portfolio
Mirati Therapeutics, long speculated to be a potential acquisition target in the world of Big Pharma, has now sealed a ...
Sanofi Considers Acquisition of Mirati Amid Intensifying KRAS Cancer Drug Battle, Reports Bloomberg
Mirati Therapeutics experienced a significant surge in its stock price on Thursday, triggered by swirling rumors of a potential acquisition ...
FDA Convenes Advisors to Assess Full Approval Prospects for Amgen’s Lumakras Amid KRAS Uncertainties
Amgen faces a critical juncture with its pioneering KRAS inhibitor, Lumakras, as uncertainties loom over its potential combinability with standard ...
Mirati fires its CEO and announces a new lung cancer Krazati-Keytruda study strategy
Following the successful approval of the KRAS inhibitor Krazati, Mirati Therapeutics’ CEO David Meek has made an abrupt exit from ...
Mirati’s KRAS Inhibitor Krazati Faces Rejection in Europe
Source – Mirati Therapeutics Mirati Therapeutics has faced a setback in its quest to market its lead KRAS inhibitor Krazati, ...
